Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18237542 | 0.84 | GSK3B (0.34) | CHRNB2CHRNA4TP53GSK3B | |
| SCHEMBL1698223 | 0.76 | OPRL1 (0.40) | OPRL1 | |
| SCHEMBL1698222 | 0.73 | CXCR4 (0.44) | — | |
| SCHEMBL19153952 | 0.73 | GSK3B (0.40) | CHRNB2CHRNA4GSK3BOPRL1 | |
| SCHEMBL1698199 | 0.70 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL18259028 | 0.69 | KDM1A (0.34) | CHRNB2CHRNA4GSK3B | |
| SCHEMBL31669380 | 0.69 | GSK3B (0.33) | GSK3B | |
| SCHEMBL21920702 | 0.69 | FNTA (0.33) | CHRNB2CHRNA4GSK3B | |
| SCHEMBL1698226 | 0.69 | CXCR4 (0.41) | — | |
| SCHEMBL19435835 | 0.68 | CXCR4 (0.40) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | GBA1, GBA2, GAA | CHRNB2 2016/4885CHRNA4 2368/4885TP53 1694/4885 |
| US-11739072-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | CHRNB2 2016/4885CHRNA4 2368/4885TP53 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.